You just read:

IDELVION® -- CSL Behring's Innovative Therapy for Hemophilia B Patients -- Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration

News provided by

CSL Behring

11 May, 2016, 13:30 ET